[Oncology PET radiopharmaceuticals in clinic and research in 2020].

This article discusses, among others, radiopharmaceuticals labelled with 18F and 68Ga isotopes required for the diagnosis of neuroendocrine and prostate tumours, furthermore the inhibitors of the fibroblast activation protein. The increasing variety of metallic radioisotopes (44Sc, 64Cu, 52Mn, 86Y, 89Zr) will help meet the need for new biomarkers and will greatly facilitate the introduction of the new generation of PET radiopharmaceuticals.
PMID: 32520003 [PubMed - in process]

Source: Magyar Onkologia - June 9, 2020 Category: Cancer & Oncology Authors: Mikecz P, Fekete A, Tóth G, Környei J, Bali T, Cservenyák T, Borbély K Tags: Magy Onkol Source Type: research